Bevirimat

Bevirimat
Clinical data
Other names	PA-457; 3-O-(3',3'-dimethylsuccinyl)-betulinic acid
Routes of; administration	Oral
ATC code	none;
Pharmacokinetic data
Metabolism	Hepatic glucuronidation (UGT1A3-mediated)
Elimination half-life	56.3 to 69.5 hours
Excretion	Fecal
Identifiers
	IUPAC name (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid;
CAS Number	174022-42-5 ;
PubChem CID	457928;
ChemSpider	403003 ;
UNII	S125DW66N8;
ChEMBL	ChEMBL404519 ;
NIAID ChemDB	028530;
CompTox Dashboard (EPA)	DTXSID20169749 ;
ECHA InfoCard	100.125.475
Chemical and physical data
Formula	C36H56O6
Molar mass	584.838 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O;
	InChI InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1 ; Key:YJEJKUQEXFSVCJ-WRFMNRASSA-N ;
	(what is this?) (verify)

Bevirimat (research code MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound, first isolated from Syzygium claviflorum, a Chinese herb. It is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition. It is not currently U.S. Food and Drug Administration (FDA) approved. It was originally developed by the pharmaceutical company Panacos and reached Phase IIb clinical trials. Myriad Genetics announced on January 21, 2009 the acquisition of all rights to bevirimat for $7M USD. On June 8, 2010 Myriad Genetics announced that it was abandoning their HIV portfolio to focus more on cancer drug development.